Immunology of Inflammatory Bowel Disease and Molecular Targets for Biologics

Gastroenterology Clinics of North America

Volumn 43, Issue 3, 2014, Pages 405-424

  Dave, Maneesh ^a   Papadakis, Konstantinos A ^a   Faubion Jr , William A ^a  

^a MAYO CLINIC   (United States)

Author keywords

Adaptive immunity; Biologics; IBD; Immunology; Innate immunity

Indexed keywords

BIOLOGICAL PRODUCT;

ADAPTIVE IMMUNITY; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL PRACTICE; CROHN DISEASE; CYTOMETRY; DENDRITIC CELL; DRUG DESIGN; DRUG MECHANISM; DRUG RESEARCH; EPITHELIAL BARRIER; GAMMA DELTA T LYMPHOCYTE; GENE LINKAGE DISEQUILIBRIUM; HIGH THROUGHPUT SEQUENCING; HUMAN; IMMUNOPATHOGENESIS; IMMUNOPATHOLOGY; INFLAMMATORY BOWEL DISEASE; INNATE IMMUNITY; INTESTINE FLORA; MACROPHAGE FUNCTION; MASS CYTOMETRY; MOLECULAR GENETICS; MOLECULARLY TARGETED THERAPY; MUCOSAL IMMUNITY; NATURAL KILLER T CELL; NONHUMAN; PERMEABILITY BARRIER; PERSONALIZED MEDICINE; REGULATORY T LYMPHOCYTE; REVIEW; SEQUENCE ANALYSIS; T LYMPHOCYTE; ULCERATIVE COLITIS; ANIMAL; IMMUNOLOGY; INFLAMMATORY BOWEL DISEASES; INTESTINE; MACROPHAGE; MICROBIOLOGY; MICROFLORA;

ANIMALS; DENDRITIC CELLS; HUMANS; IMMUNITY, INNATE; IMMUNITY, MUCOSAL; INFLAMMATORY BOWEL DISEASES; INTESTINES; MACROPHAGES; MICROBIOTA; T-LYMPHOCYTES;

EID: 84905676302     PISSN: 08898553     EISSN: 15581942     Source Type: Journal    
DOI: 10.1016/j.gtc.2014.05.003     Document Type: Review

References (127)

1. Molodecky N.A., Soon I.S., Rabi D.M., et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012, 142:46-54.e42. [quiz: e30].
2. Terdiman J.P., Gruss C.B., Heidelbaugh J.J., et al. American Gastroenterological Association Institute guideline on the use of thiopurines, methotrexate, and anti-TNF-alpha biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease. Gastroenterology 2013, 145:1459-1463.
3. Vogelaar L., Spijker A.V., van der Woude C.J. The impact of biologics on health-related quality of life in patients with inflammatory bowel disease. Clin Exp Gastroenterol 2009, 2:101-109.
4. Bernstein C.N., Loftus E.V., Ng S.C., et al. Hospitalisations and surgery in Crohn's disease. Gut 2012, 61:622-629.
5. Abraham C., Cho J.H. Inflammatory bowel disease. N Engl J Med 2009, 361:2066-2078.
6. Murphy K. Janeway's immunobiology 2011, Garland Science, New York.
7. Barker N., van Es J.H., Kuipers J., et al. Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature 2007, 449:1003-1007.
8. Fasano A., Shea-Donohue T. Mechanisms of disease: the role of intestinal barrier function in the pathogenesis of gastrointestinal autoimmune diseases. Nat Clin Pract Gastroenterol Hepatol 2005, 2:416-422.
9. Tripathi A., Lammers K.M., Goldblum S., et al. Identification of human zonulin, a physiological modulator of tight junctions, as prehaptoglobin-2. Proc Natl Acad Sci U S A 2009, 106:16799-16804.
10. Fagarasan S., Honjo T. Intestinal IgA synthesis: regulation of front-line body defences. Nat Rev Immunol 2003, 3:63-72.
11. Ganz T. Defensins: antimicrobial peptides of innate immunity. Nat Rev Immunol 2003, 3:710-720.
12. Harwig S.S., Tan L., Qu X.D., et al. Bactericidal properties of murine intestinal phospholipase A2. J Clin Invest 1995, 95:603-610.
13. Newberry R.D., Lorenz R.G. Organizing a mucosal defense. Immunol Rev 2005, 206:6-21.
14. Owen R.L., Bhalla D.K. Cytochemical analysis of alkaline phosphatase and esterase activities and of lectin-binding and anionic sites in rat and mouse Peyer's patch M cells. Am J Anat 1983, 168:199-212.
15. Pappo J., Owen R.L. Absence of secretory component expression by epithelial cells overlying rabbit gut-associated lymphoid tissue. Gastroenterology 1988, 95:1173-1177.
16. Ayabe T., Satchell D.P., Wilson C.L., et al. Secretion of microbicidal alpha-defensins by intestinal Paneth cells in response to bacteria. Nat Immunol 2000, 1:113-118.
17. Vaishnava S., Behrendt C.L., Ismail A.S., et al. Paneth cells directly sense gut commensals and maintain homeostasis at the intestinal host-microbial interface. Proc Natl Acad Sci U S A 2008, 105:20858-20863.
18. Lee S.H., Starkey P.M., Gordon S. Quantitative analysis of total macrophage content in adult mouse tissues. Immunochemical studies with monoclonal antibody F4/80. J Exp Med 1985, 161:475-489.
19. Smith P.D., Ochsenbauer-Jambor C., Smythies L.E. Intestinal macrophages: unique effector cells of the innate immune system. Immunol Rev 2005, 206:149-159.
20. Wahl S.M., Hunt D.A., Wakefield L.M., et al. Transforming growth factor type beta induces monocyte chemotaxis and growth factor production. Proc Natl Acad Sci U S A 1987, 84:5788-5792.
21. Bamias G., Corridoni D., Pizarro T.T., et al. New insights into the dichotomous role of innate cytokines in gut homeostasis and inflammation. Cytokine 2012, 59:451-459.
22. Steinbach E.C., Plevy S.E. The role of macrophages and dendritic cells in the initiation of inflammation in IBD. Inflamm Bowel Dis 2014, 20:166-175.
23. Mosser D.M., Edwards J.P. Exploring the full spectrum of macrophage activation. Nat Rev Immunol 2008, 8:958-969.
24. Niess J.H., Brand S., Gu X., et al. CX3CR1-mediated dendritic cell access to the intestinal lumen and bacterial clearance. Science 2005, 307:254-258.
25. Lelouard H., Fallet M., de Bovis B., et al. Peyer's patch dendritic cells sample antigens by extending dendrites through M cell-specific transcellular pores. Gastroenterology 2012, 142:592-601.e3.
26. Hart A.L., Al-Hassi H.O., Rigby R.J., et al. Characteristics of intestinal dendritic cells in inflammatory bowel diseases. Gastroenterology 2005, 129:50-65.
27. Menning A., Loddenkemper C., Westendorf A.M., et al. Retinoic acid-induced gut tropism improves the protective capacity of Treg in acute but not in chronic gut inflammation. Eur J Immunol 2010, 40:2539-2548.
28. Mora J.R., Bono M.R., Manjunath N., et al. Selective imprinting of gut-homing T cells by Peyer's patch dendritic cells. Nature 2003, 424:88-93.
29. Hayday A., Theodoridis E., Ramsburg E., et al. Intraepithelial lymphocytes: exploring the Third Way in immunology. Nat Immunol 2001, 2:997-1003.
30. Kanamori Y., Ishimaru K., Nanno M., et al. Identification of novel lymphoid tissues in murine intestinal mucosa where clusters of c-kit+ IL-7R+ Thy1+ lympho-hemopoietic progenitors develop. J Exp Med 1996, 184:1449-1459.
31. Groh V., Steinle A., Bauer S., et al. Recognition of stress-induced MHC molecules by intestinal epithelial gammadelta T cells. Science 1998, 279:1737-1740.
32. Thedrez A., Sabourin C., Gertner J., et al. Self/non-self discrimination by human gammadelta T cells: simple solutions for a complex issue?. Immunol Rev 2007, 215:123-135.
33. Carding S.R., Egan P.J. Gammadelta T cells: functional plasticity and heterogeneity. Nat Rev Immunol 2002, 2:336-345.
34. Godfrey D.I., MacDonald H.R., Kronenberg M., et al. NKT cells: what's in a name?. Nat Rev Immunol 2004, 4:231-237.
35. Fuss I.J., Heller F., Boirivant M., et al. Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis. J Clin Invest 2004, 113:1490-1497.
36. Ogura Y., Bonen D.K., Inohara N., et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001, 411:603-606.
37. Hugot J.P., Chamaillard M., Zouali H., et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001, 411:599-603.
38. Kobayashi K.S., Chamaillard M., Ogura Y., et al. Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science 2005, 307:731-734.
39. Maeda S., Hsu L.C., Liu H., et al. Nod2 mutation in Crohn's disease potentiates NF-kappaB activity and IL-1beta processing. Science 2005, 307:734-738.
40. Targan S.R., Hanauer S.B., van Deventer S.J., et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997, 337:1029-1035.
41. Rutgeerts P., Sandborn W.J., Feagan B.G., et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005, 353:2462-2476.
42. Orenstein R. Anti-interleukin-12 antibody for active Crohn's disease. N Engl J Med 2005, 352:627-628.
43. Sandborn W.J., Gasink C., Gao L.L., et al. Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N Engl J Med 2012, 367:1519-1528.
44. Marks D.J., Harbord M.W., MacAllister R., et al. Defective acute inflammation in Crohn's disease: a clinical investigation. Lancet 2006, 367:668-678.
45. Boya P., Reggiori F., Codogno P. Emerging regulation and functions of autophagy. Nat Cell Biol 2013, 15:713-720.
46. Rioux J.D., Xavier R.J., Taylor K.D., et al. Genome-wide association study identifies new susceptibility loci for Crohn disease and implicates autophagy in disease pathogenesis. Nat Genet 2007, 39:596-604.
47. McCarroll S.A., Huett A., Kuballa P., et al. Deletion polymorphism upstream of IRGM associated with altered IRGM expression and Crohn's disease. Nat Genet 2008, 40:1107-1112.
48. Walter P., Ron D. The unfolded protein response: from stress pathway to homeostatic regulation. Science 2011, 334:1081-1086.
49. Treton X., Pedruzzi E., Cazals-Hatem D., et al. Altered endoplasmic reticulum stress affects translation in inactive colon tissue from patients with ulcerative colitis. Gastroenterology 2011, 141:1024-1035.
50. Khor B., Gardet A., Xavier R.J. Genetics and pathogenesis of inflammatory bowel disease. Nature 2011, 474:307-317.
51. Kaser A., Lee A.H., Franke A., et al. XBP1 links ER stress to intestinal inflammation and confers genetic risk for human inflammatory bowel disease. Cell 2008, 134:743-756.
52. Jenkins R.T., Ramage J.K., Jones D.B., et al. Small bowel and colonic permeability to 51Cr-EDTA in patients with active inflammatory bowel disease. Clin Invest Med 1988, 11:151-155.
53. Wyatt J., Oberhuber G., Pongratz S., et al. Increased gastric and intestinal permeability in patients with Crohn's disease. Am J Gastroenterol 1997, 92:1891-1896.
54. Hollander D., Vadheim C.M., Brettholz E., et al. Increased intestinal permeability in patients with Crohn's disease and their relatives. A possible etiologic factor. Ann Intern Med 1986, 105:883-885.
55. Teahon K., Smethurst P., Levi A.J., et al. Intestinal permeability in patients with Crohn's disease and their first degree relatives. Gut 1992, 33:320-323.
56. Olson T.S., Reuter B.K., Scott K.G., et al. The primary defect in experimental ileitis originates from a nonhematopoietic source. J Exp Med 2006, 203:541-552.
57. Jostins L., Ripke S., Weersma R.K., et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 2012, 491:119-124.
58. Kiesslich R., Duckworth C.A., Moussata D., et al. Local barrier dysfunction identified by confocal laser endomicroscopy predicts relapse in inflammatory bowel disease. Gut 2012, 61(8):1146-1153.
59. McGuckin M.A., Eri R., Simms L.A., et al. Intestinal barrier dysfunction in inflammatory bowel diseases. Inflamm Bowel Dis 2009, 15:100-113.
60. Sigthorsson G., Tibble J., Hayllar J., et al. Intestinal permeability and inflammation in patients on NSAIDs. Gut 1998, 43:506-511.
61. Ananthakrishnan A.N., Higuchi L.M., Huang E.S., et al. Aspirin, nonsteroidal anti-inflammatory drug use, and risk for Crohn disease and ulcerative colitis: a cohort study. Ann Intern Med 2012, 156:350-359.
62. Roberts C.L., Keita A.V., Duncan S.H., et al. Translocation of Crohn's disease Escherichia coli across M-cells: contrasting effects of soluble plant fibres and emulsifiers. Gut 2010, 59:1331-1339.
63. Ananthakrishnan A.N., Khalili H., Konijeti G.G., et al. A prospective study of long-term intake of dietary fiber and risk of Crohn's disease and ulcerative colitis. Gastroenterology 2013, 145:970-977.
64. Prager M., Buttner J., Haas V., et al. The JAK2 variant rs10758669 in Crohn's disease: altering the intestinal barrier as one mechanism of action. Int J Colorectal Dis 2012, 27(5):565-573.
65. Stoll M., Corneliussen B., Costello C.M., et al. Genetic variation in DLG5 is associated with inflammatory bowel disease. Nat Genet 2004, 36:476-480.
66. Gunther C., Martini E., Wittkopf N., et al. Caspase-8 regulates TNF-alpha-induced epithelial necroptosis and terminal ileitis. Nature 2011, 477:335-339.
67. Gunn M.D., Tangemann K., Tam C., et al. A chemokine expressed in lymphoid high endothelial venules promotes the adhesion and chemotaxis of naive T lymphocytes. Proc Natl Acad Sci U S A 1998, 95:258-263.
68. Weaver C.T., Harrington L.E., Mangan P.R., et al. Th17: an effector CD4 T cell lineage with regulatory T cell ties. Immunity 2006, 24:677-688.
69. Iwakura Y., Ishigame H. The IL-23/IL-17 axis in inflammation. J Clin Invest 2006, 116:1218-1222.
70. Matloubian M., Lo C.G., Cinamon G., et al. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 2004, 427:355-360.
71. Shiow L.R., Rosen D.B., Brdickova N., et al. CD69 acts downstream of interferon-alpha/beta to inhibit S1P1 and lymphocyte egress from lymphoid organs. Nature 2006, 440:540-544.
72. Johansson-Lindbom B., Svensson M., Pabst O., et al. Functional specialization of gut CD103+ dendritic cells in the regulation of tissue-selective T cell homing. J Exp Med 2005, 202:1063-1073.
73. Berlin C., Berg E.L., Briskin M.J., et al. Alpha 4 beta 7 integrin mediates lymphocyte binding to the mucosal vascular addressin MAdCAM-1. Cell 1993, 74:185-195.
74. Briskin M., Winsor-Hines D., Shyjan A., et al. Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue. Am J Pathol 1997, 151:97-110.
75. Maloy K.J., Powrie F. Intestinal homeostasis and its breakdown in inflammatory bowel disease. Nature 2011, 474:298-306.
76. Shevach E.M. From vanilla to 28 flavors: multiple varieties of T regulatory cells. Immunity 2006, 25:195-201.
77. Mottet C., Uhlig H.H., Powrie F. Cutting edge: cure of colitis by CD4+CD25+ regulatory T cells. J Immunol 2003, 170:3939-3943.
78. Sakaguchi S., Sakaguchi N., Asano M., et al. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995, 155:1151-1164.
79. Maul J., Loddenkemper C., Mundt P., et al. Peripheral and intestinal regulatory CD4+ CD25(high) T cells in inflammatory bowel disease. Gastroenterology 2005, 128:1868-1878.
80. Saruta M., Yu Q.T., Fleshner P.R., et al. Characterization of FOXP3+CD4+ regulatory T cells in Crohn's disease. Clin Immunol 2007, 125:281-290.
81. Yu Q.T., Saruta M., Avanesyan A., et al. Expression and functional characterization of FOXP3+ CD4+ regulatory T cells in ulcerative colitis. Inflamm Bowel Dis 2007, 13:191-199.
82. Fantini M.C., Rizzo A., Fina D., et al. Smad7 controls resistance of colitogenic T cells to regulatory T cell-mediated suppression. Gastroenterology 2009, 136:1308-1316. e1-3.
83. Nguyen D.D., Snapper S.B. Targeting Smads to restore transforming growth factor-beta signaling and regulatory T-cell function in inflammatory bowel disease. Gastroenterology 2009, 136:1161-1164.
84. Conley M.E., Delacroix D.L. Intravascular and mucosal immunoglobulin A: two separate but related systems of immune defense?. Ann Intern Med 1987, 106:892-899.
85. Brandtzaeg P., Farstad I.N., Johansen F.E., et al. The B-cell system of human mucosae and exocrine glands. Immunol Rev 1999, 171:45-87.
86. Brandtzaeg P., Prydz H. Direct evidence for an integrated function of J chain and secretory component in epithelial transport of immunoglobulins. Nature 1984, 311:71-73.
87. Macpherson A.J., Uhr T. Induction of protective IgA by intestinal dendritic cells carrying commensal bacteria. Science 2004, 303:1662-1665.
88. Powrie F., Leach M.W., Mauze S., et al. Inhibition of Th1 responses prevents inflammatory bowel disease in scid mice reconstituted with CD45RBhi CD4+ T cells. Immunity 1994, 1:553-562.
89. Sugawara K., Olson T.S., Moskaluk C.A., et al. Linkage to peroxisome proliferator-activated receptor-gamma in SAMP1/YitFc mice and in human Crohn's disease. Gastroenterology 2005, 128:351-360.
90. Totsuka T., Kanai T., Uraushihara K., et al. Therapeutic effect of anti-OX40L and anti-TNF-alpha MAbs in a murine model of chronic colitis. Am J Physiol Gastrointest Liver Physiol 2003, 284:10.
91. Hovhannisyan Z., Treatman J., Littman D.R., et al. Characterization of interleukin-17-producing regulatory T cells in inflamed intestinal mucosa from patients with inflammatory bowel diseases. Gastroenterology 2011, 140:957-965.
92. Pariente B., Mocan I., Camus M., et al. Activation of the receptor NKG2D leads to production of Th17 cytokines in CD4+ T cells of patients with Crohn's disease. Gastroenterology 2011, 141:217-226. 226.e1-2.
93. Di Meglio P., Di Cesare A., Laggner U., et al. The IL23R R381Q gene variant protects against immune-mediated diseases by impairing IL-23-induced Th17 effector response in humans. PLoS One 2011, 6:e17160.
94. Danese S. New therapies for inflammatory bowel disease: from the bench to the bedside. Gut 2012, 61:918-932.
95. Probert C.S., Chott A., Turner J.R., et al. Persistent clonal expansions of peripheral blood CD4+ lymphocytes in chronic inflammatory bowel disease. J Immunol 1996, 157:3183-3191.
96. Cong Y., Brandwein S.L., McCabe R.P., et al. CD4+ T cells reactive to enteric bacterial antigens in spontaneously colitic C3H/HeJBir mice: increased T helper cell type 1 response and ability to transfer disease. J Exp Med 1998, 187:855-864.
97. Lodes M.J., Cong Y., Elson C.O., et al. Bacterial flagellin is a dominant antigen in Crohn disease. J Clin Invest 2004, 113:1296-1306.
98. Dave M., Higgins P.D., Middha S., et al. The human gut microbiome: current knowledge, challenges, and future directions. Transl Res 2012, 160:246-257.
99. Maynard C.L., Elson C.O., Hatton R.D., et al. Reciprocal interactions of the intestinal microbiota and immune system. Nature 2012, 489:231-241.
100. Chassaing B., Darfeuille-Michaud A. The commensal microbiota and enteropathogens in the pathogenesis of inflammatory bowel diseases. Gastroenterology 2011, 140:1720-1728.
101. Nell S., Suerbaum S., Josenhans C. The impact of the microbiota on the pathogenesis of IBD: lessons from mouse infection models. Nat Rev Microbiol 2010, 8:564-577.
102. Sansonetti P.J. War and peace at mucosal surfaces. Nat Rev Immunol 2004, 4:953-964.
103. Cario E., Gerken G., Podolsky D.K. Toll-like receptor 2 enhances ZO-1-associated intestinal epithelial barrier integrity via protein kinase C. Gastroenterology 2004, 127:224-238.
104. Rakoff-Nahoum S., Paglino J., Eslami-Varzaneh F., et al. Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell 2004, 118:229-241.
105. Hisamatsu T., Suzuki M., Reinecker H.C., et al. CARD15/NOD2 functions as an antibacterial factor in human intestinal epithelial cells. Gastroenterology 2003, 124:993-1000.
106. Wehkamp J., Harder J., Weichenthal M., et al. NOD2 (CARD15) mutations in Crohn's disease are associated with diminished mucosal alpha-defensin expression. Gut 2004, 53:1658-1664.
107. Lala S., Ogura Y., Osborne C., et al. Crohn's disease and the NOD2 gene: a role for Paneth cells. Gastroenterology 2003, 125:47-57.
108. Biswas A., Liu Y.J., Hao L., et al. Induction and rescue of Nod2-dependent Th1-driven granulomatous inflammation of the ileum. Proc Natl Acad Sci U S A 2010, 107:14739-14744.
109. Cadwell K., Patel K.K., Maloney N.S., et al. Virus-plus-susceptibility gene interaction determines Crohn's disease gene Atg16L1 phenotypes in intestine. Cell 2010, 141:1135-1145.
110. Murthy A., Li Y., Peng I., et al. A Crohn's disease variant in Atg16l1 enhances its degradation by caspase 3. Nature 2014, 506:456-462.
111. Hamilton M.J., Snapper S.B., Blumberg R.S. Update on biologic pathways in inflammatory bowel disease and their therapeutic relevance. J Gastroenterol 2012, 47(1):1-8.
112. Bevan M.J. Cross-priming. Nat Immunol 2006, 7:363-365.
113. Sutmuller R.P., Morgan M.E., Netea M.G., et al. Toll-like receptors on regulatory T cells: expanding immune regulation. Trends Immunol 2006, 27:387-393.
114. Garrett W.S., Lord G.M., Punit S., et al. Communicable ulcerative colitis induced by T-bet deficiency in the innate immune system. Cell 2007, 131:33-45.
115. Bach J.F. The effect of infections on susceptibility to autoimmune and allergic diseases. N Engl J Med 2002, 347:911-920.
116. Olszak T., An D., Zeissig S., et al. Microbial exposure during early life has persistent effects on natural killer T cell function. Science 2012, 336:489-493.
117. McFall-Ngai M. Adaptive immunity: care for the community. Nature 2007, 445:153.
118. Hueber W., Sands B.E., Lewitzky S., et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut 2012, 61:1693-1700.
119. Ivanov I.I., Atarashi K., Manel N., et al. Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell 2009, 139:485-498.
120. Colombel J.F., Sendid B., Jouault T., et al. Secukinumab failure in Crohn's disease: the yeast connection?. Gut 2013, 62:800-801.
121. Pavlick K.P., Laroux F.S., Fuseler J., et al. Role of reactive metabolites of oxygen and nitrogen in inflammatory bowel disease. Free Radic Biol Med 2002, 33:311-322.
122. Macdonald T.T., Monteleone G. Immunity, inflammation, and allergy in the gut. Science 2005, 307:1920-1925.
123. Newell E.W., Sigal N., Bendall S.C., et al. Cytometry by time-of-flight shows combinatorial cytokine expression and virus-specific cell niches within a continuum of CD8+ T cell phenotypes. Immunity 2012, 36:142-152.
124. Chattopadhyay P.K., Gierahn T.M., Roederer M., et al. Single-cell technologies for monitoring immune systems. Nat Immunol 2014, 15:128-135.
125. Kidd B.A., Peters L.A., Schadt E.E., et al. Unifying immunology with informatics and multiscale biology. Nat Immunol 2014, 15:118-127.
126. Virgin H.W., Todd J.A. Metagenomics and personalized medicine. Cell 2011, 147:44-56.
127. Zitnik M., Janjic V., Larminie C., et al. Discovering disease-disease associations by fusing systems-level molecular data. Sci Rep 2013, 3:3202.